Want to see KR:249420 full AI Analyst Report?
Ildong Pharmaceutical Co., Ltd. (249420) Financial Statements
Ildong Pharmaceutical Co., Ltd. Financial Overview
Ildong Pharmaceutical Co., Ltd.'s market cap is currently $397.78B. The company's EPS TTM is $1418.03; its P/E ratio is 8.87; and it has a dividend yield of 1.59%. Ildong Pharmaceutical Co., Ltd. is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 566.93B | $ 614.94B | $ 600.76B | $ 637.71B | $ 560.13B |
| Gross Profit | $ 214.76B | $ 233.46B | $ 207.54B | $ 236.34B | $ 219.44B |
| Operating Income | $ 17.32B | $ 13.12B | $ -53.42B | $ -73.33B | $ -54.38B |
| EBITDA | $ 39.90B | $ 33.59B | $ -51.23B | $ -80.49B | $ -101.34B |
| Net Income | $ 27.66B | $ -4.58B | $ -78.93B | $ -142.17B | $ -99.71B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 64.96B | $ 84.87B | $ 81.28B | $ 78.75B | $ 154.68B |
| Total Assets | $ 573.03B | $ 589.04B | $ 611.26B | $ 655.81B | $ 708.97B |
| Total Debt | $ 150.31B | $ 205.55B | $ 212.73B | $ 207.75B | $ 226.16B |
| Net Debt | $ 85.46B | $ 133.28B | $ 159.47B | $ 155.60B | $ 90.57B |
| Total Liabilities | $ 333.52B | $ 429.99B | $ 437.00B | $ 457.59B | $ 548.39B |
| Stockholders' Equity | $ 246.42B | $ 160.76B | $ 169.54B | $ 191.24B | $ 152.91B |
| Cash Flow | |||||
| Free Cash Flow | $ 5.30B | $ 14.24B | $ -54.80B | $ -73.15B | $ -31.16B |
| Operating Cash Flow | $ 18.95B | $ 28.29B | $ -36.62B | $ -53.54B | $ -11.37B |
| Investing Cash Flow | $ -2.28B | $ 18.46B | $ -20.36B | $ -26.44B | $ -43.37B |
| Financing Cash Flow | $ -24.09B | $ -27.85B | $ 58.15B | $ -3.29B | $ 104.32B |
Currency in KRW